Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05335434 · ClinicalTrials.gov registry record · NA
Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation
A NA study of Oral Mucositis and Myeloablative Allogeneic Hematopoietic Cell Transplantation, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05335434 is a NA study of Oral Mucositis and Myeloablative Allogeneic Hematopoietic Cell Transplantation that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 20 participants, below the 106-participant average among 10 other Oral Mucositis trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05335434, a NA study of Oral Mucositis and Myeloablative Allogeneic Hematopoietic Cell Transplantation, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center pilot study evaluating intraoral photobiomodulation for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (alloHCT). Patients who are planned for alloHCT will receive daily intraoral photobiomodulation therapy (PBMT) using a novel LED device. The name of the study device involved in this study is: \- THOR LX2.3 with LED Lollipop
Conditions Studied
Interventions
- DEVICE THOR LX2.3 with LED Lollipop
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-06-10 |
| Est. Completion | 2026-07-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05335434
The ClinicalTrials.gov registry entry for NCT05335434 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 10 other Oral Mucositis trials with a reported enrollment target (81% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Oral Mucositis appearing as the primary indexed condition, and to 1 intervention - of which THOR LX2.3 with LED Lollipop is the first listed.
NCT05335434 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05335434 about?
NCT05335434 is a clinical study titled "Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation". This is a single center pilot study evaluating intraoral photobiomodulation for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (alloHCT). Patients who are planned for alloHCT will receive daily intraoral photobiomodulation therapy ...
What is the current status of trial NCT05335434?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2022-06-10. Estimated completion is 2026-07-19.
What conditions does trial NCT05335434 study?
This clinical trial studies the following conditions: Oral Mucositis, Myeloablative Allogeneic Hematopoietic Cell Transplantation, Intraoral Photobiomodulation Therapy, Mucosal Ulcer.
What interventions are being tested in trial NCT05335434?
The interventions under investigation include: THOR LX2.3 with LED Lollipop (DEVICE).
Who is sponsoring clinical trial NCT05335434?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05335434 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oral Mucositis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
F.L.O.S.S. Project (Facilitated Lessons on Oral and Systemic Health in Survivors)
RECRUITING · NA
-
Prevention of Oral Mucositis Using Photobiomodulation Therapy
COMPLETED · NA
-
Coconut Oil to Prevent Mouth Sores in Pediatric Patients Receiving High Dose Chemotherapy
RECRUITING · Phase 2
-
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
RECRUITING · Phase 2
-
Photobiomodulation for the Prevention of Oral Mucositis
ACTIVE NOT RECRUITING · Phase 2
-
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Oral Mucositis
All registered trials for this condition
Myeloablative Allogeneic Hematopoietic Cell Transplantation
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.